How This Evidence Evolved
Giant Cell Arteritis Management
From prolonged glucocorticoid dependence to IL-6 receptor blockade as steroid-sparing therapy
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
Sensitivity for GCA diagnosis (both tests within 10 days of starting treatment): ultrasound 54% (95% CI 48-60%) vs temporal artery biopsy 39% (95% CI 33-46%); specificity 81% (95% CI 73-88%) vs 100% (95% CI 97-100%)
Tocilizumab-free, glucocorticoid-free remission through 2-year part two after stopping weekly tocilizumab in remission at 1 year: 25/59 (42%); median cumulative glucocorticoid dose over 3 years: weekly tocilizumab 2647 mg vs placebo 5277 mg (26-week taper) and 5323 mg (52-week taper) (van Elteren p≤0.001)
Sustained remission at week 52 (36 patients analysed): sarilumab 200 mg + 26-week taper 6/13 (46%) and 150 mg + 26-week taper 3/7 (43%) vs placebo + 52-week taper 3/10 (30%) and placebo + 26-week taper 0/6 (no p values; authors: clear conclusions difficult)
Integration into clinical practice guidelines and recommendations
Current standard of care and ongoing research directions
Relapse-free survival at 12 months: continued abatacept 48% vs switch to placebo 31% (P=.049)
Sustained remission at 52 weeks: SEC-300/26-week taper 25.6% vs placebo/52-week taper 16.9% (difference 8.7pp, 95% CI −1.3 to 18.8; P=.09)
Time to flare by week 26: mavrilimumab vs placebo HR 0.38 (95% CI 0.15–0.92; P=.026)
Landmark Trials in This Story
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
GCA classification: ≥3 of 5 criteria; sensitivity 93.5%, specificity 91.2% versus other vasculitides
Trial of Tocilizumab in Giant-Cell Arteritis
Sustained glucocorticoid-free remission at 52 weeks: 56% (weekly TCZ) and 53% (q2w TCZ) vs 14% (placebo/26-wk taper) and 18% (placebo/52-wk taper); p<0.001
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.
Sensitivity for GCA diagnosis (both tests within 10 days of starting treatment): ultrasound 54% (95% CI 48-60%) vs temporal artery biopsy 39% (95% CI 33-46%); specificity 81% (95% CI 73-88%) vs 100% (95% CI 97-100%)
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
Tocilizumab-free, glucocorticoid-free remission through 2-year part two after stopping weekly tocilizumab in remission at 1 year: 25/59 (42%); median cumulative glucocorticoid dose over 3 years: weekly tocilizumab 2647 mg vs placebo 5277 mg (26-week taper) and 5323 mg (52-week taper) (van Elteren p≤0.001)
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.
Sustained remission at week 52 (36 patients analysed): sarilumab 200 mg + 26-week taper 6/13 (46%) and 150 mg + 26-week taper 3/7 (43%) vs placebo + 52-week taper 3/10 (30%) and placebo + 26-week taper 0/6 (no p values; authors: clear conclusions difficult)
A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.
Relapse-free survival at 12 months: continued abatacept 48% vs switch to placebo 31% (P=.049)
Secukinumab for Giant Cell Arteritis.
Sustained remission at 52 weeks: SEC-300/26-week taper 25.6% vs placebo/52-week taper 16.9% (difference 8.7pp, 95% CI −1.3 to 18.8; P=.09)
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Time to flare by week 26: mavrilimumab vs placebo HR 0.38 (95% CI 0.15–0.92; P=.026)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.